Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Download All
Experts discuss how they incorporate BCMA-targeted agents into the treatment of patients with MM and manage toxicities associated with these agents. This program features ClinicalThought commentaries, downloadable slides, and an on-demand webcast from a live webinar.
Sagar Lonial, MD

ClinicalThought

How I am using currently approved anti-BCMA agents as a part of the treatment plan for patients with R/R MM.

Sagar Lonial, MD Released: September 9, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue